References
- Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): Definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 2003;54:3–24.
- Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465–75.
- Heinrich MC, Corless CL. Gastric GI stromal tumors (GISTs): The role of surgery in the era of targeted therapy. J Surg Oncol 2005;90:195–207.
- Samiian L, Weaver M, Velanovich V. Evaluation of gastrointestinal stromal tumors for recurrence rates and patterns of long-term follow-up. Am Surg 2004;70:187–91.
- DeMatteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: Before and after STI-571. Hum Pathol 2002;33:466–77.
- Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, . Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279(5350): 577–80.
- Blanke CD, Rankin C, Demetri GD, Ryan CW, von MM, Benjamin RS, . Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626–32.
- Loughrey MB, Mitchell C, Mann GB, Michael M, Waring PM. Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol 2005;58:779–81.
- Katz D, Segal A, Alberton Y, Jurim O, Reissman P, Catane R, . Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anticancer Drugs 2004;15:599–602.
- Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008;13(Suppl 2):4–7.
- Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, . Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052–6.
- Shinto A, Nair N, Dutt A, Baghel NS. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib. Clin Nucl Med 2008;33:486–7.
- Choi H, Charnsangavej C, de Castro FS, Tamm EP, Benjamin RS, Johnson MM, . CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004;183:1619–28.
- Koh DM, Padhani AR. Diffusion-weighted MRI: A new functional clinical technique for tumour imaging. Br J Radiol 2006;79:633–5.
- Matsui T, Mitsui H, Sekigawa K, Kobayashi K, Okubo M, So E, . A case of a duodenal gastrointestinal stromal tumor diagnosed with the aid of diffusion-weighted magnetic resonance imaging. Clin J Gastroenterol 2009;2:384–7.
- Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 2006;6:135–43.